LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
… ProQR Strengthens Scientific Advisory Board with Leaders in … said Daniel A. de Boer, Chief Executive Officer of ProQR. “These individuals bring important scientific, … for patients living with Inherited Retinal Diseases.” ProQR’s SAB is comprised of: James Shannon, MD , Chair of the …
… ProQR to Present Data on its Axiomer® RNA Editing Technology … & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Virtual Presentation at American Association … & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … and Strabismus (AAPOS) held April 9-11, 2021. ProQR’s presentation Presentation title: A different type of …
… ProQR to Present Results from Phase 1/2 Trial of QR-421a for … & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … “Investors and Media” section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Announces Presentations at the European CF Conference … will be accessible from the Investor Relations section of ProQR’s website ( www.proqr.com ) under Events and Presentations . The archived …
… ProQR Receives Fast Track Designation from FDA for QR-421a … & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in …